FOX 26 Houston: Diakonos’s Experimental Immunotherapy for Glioblastoma Shows Promising Survival Gains in Early Trials

FOX 26 Houston reports on early clinical data from BTIF portfolio company Diakonos Oncology’s investigational dendritic cell immunotherapy for glioblastoma. The report highlights phase I trial results and features a patient currently receiving the treatment.

Diakonos’s vaccine therapy — known as Dubodencel or DOC1021 — uses a patient’s own tumor DNA to prime dendritic cells, a type of immune cell, to mount a targeted immune response against the cancer. In the phase 1 trial, 88% of patients with glioblastoma achieved 12-month survival — a population that was predominantly MGMT unmethylated, a molecular subgroup historically associated with poorer treatment response. A phase II multicenter randomized controlled trial is now underway.

View the full report from FOX 26 Houston.

Disclaimer: BTIF is not responsible for content on third-party website.